Merck's Pembrolizumab Receives FDA Orphan Drug Designation for Neuroendocrine Prostate Cancer

According to FDA, Merck & Co.'s Pembrolizumab received orphan drug designation for neuroendocrine prostate cancer (NEPC) on June 6. The designation recognizes the drug's potential to address this rare disease.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments